Tegaserod and alosetron were initially used to treat irritable bowel syndrome, but they have been withdrawn due to cardiovascular complications associated with off-targets HTR1A and HTR2B, as inferred by our model. The gene discussed is HTR2B; the disease is irritable bowel syndrome.